(via NewsDirect)
hVIVO PLC (AIM:HVO) Chief Scientific Officer
The Phase 2a clinical trial is designed as a randomised, double-blinded, placebo-controlled human challenge study and will be conducted at hVIVO's advanced quarantine facilities in
Catchpole explained that the study is scheduled to begin in the second half of 2024, with revenue recognition spread across 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers who will be subjected to controlled HRV infection. The biotechnology client recognizes the value of human challenge studies in rapidly generating early human efficacy data, which has the potential to significantly enhance the clinical asset's overall value.
Catchpole says the contract underscores hVIVO's expertise in conducting human challenge studies and its growing role in helping pharmaceutical and biotechnology companies evaluate the effectiveness of their antiviral treatments.
Contact Details
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source